Back | Next |
home / stock / crvs / crvs message board
Subject | By | Source | When |
---|---|---|---|
Good conversation you two are having. Most | flatlander_60048 | investorshub | 04/03/2023 4:27:28 AM |
Top line data for the 7 patients with | PatBoone | investorshub | 04/02/2023 11:15:52 PM |
I agree. I think we have one last | kenyonn2000 | investorshub | 04/02/2023 10:40:51 PM |
If what Richard is saying is verified with | PatBoone | investorshub | 04/02/2023 9:43:22 PM |
I think the frontline setting is a lot | kenyonn2000 | investorshub | 04/02/2023 8:28:02 PM |
Good back of the envelope calculation for the | PatBoone | investorshub | 04/02/2023 5:14:32 PM |
I agree; Im not confident in Millers business | PatBoone | investorshub | 04/02/2023 4:57:57 PM |
Looking at refractory PTCL market size, which appears | kenyonn2000 | investorshub | 04/01/2023 3:11:08 PM |
Kenyon I think you' re correct, Early clinical trial | flatlander_60048 | investorshub | 03/31/2023 7:54:14 PM |
Well, they started enrolling in early February I | kenyonn2000 | investorshub | 03/31/2023 7:36:08 PM |
I don't have any idea what the relative | flatlander_60048 | investorshub | 03/31/2023 6:04:03 PM |
Initial results from the frontline RCC combo trial | kenyonn2000 | investorshub | 03/31/2023 3:35:11 PM |
Upcoming Catalysts for $CRVS. | flatlander_60048 | investorshub | 03/31/2023 3:28:12 PM |
Upcoming Catalysts for $CRVS. | flatlander_60048 | investorshub | 03/31/2023 2:57:31 PM |
The situation you describe is pretty common with | flatlander_60048 | investorshub | 03/30/2023 5:04:14 PM |
Agree 100%. No arguing over Mille's scientific chops, | kenyonn2000 | investorshub | 03/30/2023 4:48:41 PM |
Yes, I am a $CRVS holder. Yahoo | flatlander_60048 | investorshub | 03/30/2023 4:04:30 PM |
Looking to revive interest in this board. Any | kenyonn2000 | investorshub | 03/30/2023 3:29:07 PM |
Could shoot to $4,6 or 8 a share | diversified holdings | investorshub | 04/07/2022 12:05:24 AM |
Looking for a nice run here. Setting up nicely! | diversified holdings | investorshub | 04/07/2022 12:03:58 AM |
News, Short Squeeze, Breakout and More Instantly...
Corvus Pharmaceuticals Inc. Company Name:
CRVS Stock Symbol:
NASDAQ Market:
Corvus Pharmaceuticals Inc. Website:
Soquelitinib Phase 1 Randomized Trial in Atopic Dermatitis Enrolling at Multiple Centers; Potential for Early Data Before Year-End 2024 Soquelitinib Registration Phase 3 Trial in Peripheral T Cell Lymphoma Advancing Toward Initial Enrollment in Q3 2024 Interim Data from Ciforade...
PRA Group Inc. (PRAA) is expected to report $-0.15 for Q1 2024 Bowman Consulting Group Ltd. (BWMN) is expected to report $-0.04 for Q1 2024 Noble Corporation plc A (NE) is expected to report $0.56 for Q1 2024 Velo3D Inc. (VLD) is expected to report for Q3 2024 Axon Enterprise Inc....
BURLINGAME, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, to...